

Respiratory Syncytial Virus (RSV) Vaccine

Vaccine Description	<ul style="list-style-type: none"> • Brands and types <ul style="list-style-type: none"> • ABRYSVO™: Bivalent, recombinant protein subunit • AREXVY™: Adjuvanted, monovalent, recombinant subunit • Neither vaccine contains preservatives or latex but both may have residual host cell proteins • See package inserts
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: IM (Use IM precautions for persons with bleeding disorders or receiving anticoagulant therapy) • See package inserts
Indications	<ul style="list-style-type: none"> • Individuals 60 years and older for the prevention of lower respiratory tract disease caused by RSV, using shared clinical decision making
Administrative Schedule	<ul style="list-style-type: none"> • One dose
Booster	<ul style="list-style-type: none"> • None
Contraindications	<ul style="list-style-type: none"> • History of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO™ or AREXVY™
Precautions	<ul style="list-style-type: none"> • Vaccination should be delayed for persons experiencing moderate or severe acute illness with or without fever • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration • Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting. • Vaccines may be less effective in immunocompromised persons, including those receiving immunosuppressive therapy
Special Considerations	<ul style="list-style-type: none"> • Discard vaccine if not used within 4 hours of reconstitution • See package insert for reconstitution instructions for each vaccine • See Storage and Handling Section
<p>VIS: https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.html Additional information may be found at: www.health.mil/rsv</p>	